Nartograstim

Nartograstim was approved by Pharmaceuticals and Medicals Devices Agency of Japan (PMDA) on April 1, 1994. It was originally developed by Kyowa Hakko Kiri, then marketed as Neu-up® by Yakult Honsha.

Nartograstim is a mutant recombinant human granulocyte colony-stimulating factor, which regulates the production of neutrophils within the bone marrow and affects neutrophil progenitor proliferation‚ differentiation, and selected end-cell functions. It is indicated for the treatment of patients with congenital neutropenia, idiopathic neutropenia and neutropenia associated with bone marrow transplants or chemotherapy.

Neu-up® is available as injection (lyophilized powder) for subcutaneous and intravenous use, containing 25 μg, 50 μg, 100 μg or 250 μg of Nartograstim. The recommended starting dose is 1-2 μg/kg subcutaneously or intravenously (for patients with cancer receiving chemotherapy), 8 μg/kg intravenously (for patients with bone marrow transplants), 2 μg/kg subcutaneously or 4 μg/kg intravenously (for patients with congenital neutropenia and idiopathic neutropenia) once daily.

Index：

General Information

Update Date：2015-10-26

Drug Name：
Nartograstim
Research Code：
KW-2228
Trade Name：
Neu-up®
MOA：
Stimulate the proliferation and differentiation of hematopoietic progenitor cells
Indication：
Neutropenia
Status：
Approved
Company：
Kyowa Hakko Kirin (Originator) , Yakult
Sales：
ATC Code：
Approved Countries or Area

Update Date：2015-09-07

Approval Date Approval Type Trade Name Indication Dosage Form Strength Company Review Classification
1998-01-26 New strength Neu-up Neutropenia Injection, Lyophilized powder, For solution 25 μg Yakult
1994-04-01 First approval Neu-up Neutropenia Injection, Lyophilized powder, For solution 50 μg; 100 μg; 250 μg Yakult
More
Biology Structure

Update Date：2015-09-07

Type Recombinant cytokines
Source Human
Molecular Formula C850H1344N226O245S8
Molecular Weight 18905.7
CAS No. 62683-29-8
Expression System E.coli